PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Mitomycin C

Drugs in development · updated 30 October 2026

Mitomycin C: clinical trials and development status

Other names and codes: Jelmyto, Zusduri, Mitozytrex, Mutamycin, Mitosol

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Mitomycin C is in 42 active clinical trials (recruiting or ongoing, phases I–III) for 37 diseases. The most advanced phase is III.

42Active trials
IIIMost advanced phase
37Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Mitomycin C and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 37 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Bladder neoplasmIII13NCT07566156
Non-muscle invasive bladder neoplasmIII9NCT06919965
Colorectal neoplasmIII7NCT07271355
Appendiceal neoplasmIII6NCT07271355
Anus neoplasmIII5NCT07692152
Transitional cell carcinomaIII4NCT07566156
Pseudomyxoma peritoneiIII2NCT06513065
Bladder diseaseIII1NCT07566156
Female urogenital diseaseIII1NCT07566156
GlaucomaIII1NCT06680245
Male urogenital diseaseIII1NCT07566156
NeoplasmIII1NCT07566156
Urogenital DiseasesIII1NCT07566156
Urogenital neoplasmIII1NCT07566156
Urologic DiseasesIII1NCT07566156
Urologic NeoplasmsIII1NCT07566156
Peritoneal neoplasmII5NCT04107077
Stomach neoplasmII2NCT04107077
Anal Canal CarcinomaII1NCT04166318
Breast neoplasmII1NCT02299999
Colonic neoplasmII1NCT05672108
HIV infectionII1NCT04929028
In situ carcinomaII1NCT07189793
Laryngeal papillomatosisI–II1NCT05688488
LaryngostenosisI–II1NCT05688488
Mediastinal neoplasmII1NCT05672108
Non-small-cell lung carcinomaII1NCT05672108
Pancreatic neoplasmII1NCT06233877
Pleural neoplasmII1NCT05672108
Rectal neoplasmII1NCT04929028

Everything on Mitomycin C

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch